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1. Introduction
Measuring response to locoregional treatments such
as selective internal radiation therapy (SIRT) with
yttrium-90 (90Y) microspheres is difﬁcult for a number
of reasons. First, the response assessments in oncology
are designed for systemic treatments, which in theory
would have a similar effect on all metastases throughout
the body. By contrast, locoregional treatments are
usually staged approaches targeting different tumours
sequentially over time. If a locoregional treatment is
applied in a single cycle, a 10 cm diameter tumour may
show a >50% reduction in volume; however, if during
the same interval, a new liver lesion (measuring 1 cm
in diameter) develops, the patient will be staged with
disease progression despite the signiﬁcant reduction in
tumour load. Current staging systems do not take into
account the possibility of repeat treatments (i.e. a staged
approach). This limitation applies to all tumour response
criteria, including theWorld Health Organization tumour
response criteria 1 and the Response Evaluation Criteria
In Solid Tumours (RECIST 1.0) 2 and RECIST 1.1 3 for
solid tumours, and the European Association for the
Study of the Liver (EASL) 4 and modiﬁed RECIST 5 for
hepatocellular carcinomas (HCC).
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In HCC, staging systems such as EASL and modiﬁed
RECIST have been adopted by the American Association
for the Study of Liver Diseases (AASLD) to measure the
extent of viable tissue (deﬁned as the contrast-enhancing
proportion of a tumour in the arterial phase). 5,6
Compared with RECIST, both the modiﬁed RECIST and
EASL criteria are well correlated and have signiﬁcantly
improved the assessment of overall response to anti-
angiogenic therapies (e.g. sorafenib) and locoregional
treatments (e.g. transarterial chemoembolisation [TACE])
in HCC. 7,8 However for locoregional therapies such as
TACE, there is a poor correlation between progression
rates overall compared with progression rates in tar-
get lesion, regardless of the assessment criteria used. 8
2. New concepts
Various concepts have been proposed to overcome
the limitations of current staging systems for the
assessment of the response to locoregional treatments,
such as the primary index lesion 9 or the time to
untreatable progression. 10 Riaz and colleagues, for
example, have assessed the correlation between the
imaging response in the primary index lesion and
time to progression (TTP) and overall survival with
TACE or SIRT in multifocal HCC (but not advanced
extrahepatic disease). 9 Overall, partial response using
the EASL criteria was manifest at a much earlier time
(1.6 months) compared with WHO/RECIST (7.7 months).
The researchers also found that the response seen in the
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primary index lesion following locoregional treatment
was prognostic, even in the presence of multifocal
disease. Hazard ratios using WHO and EASL were able
to capture the signiﬁcant TTP and survival beneﬁt in
responders compared with non-responders in patients
with solitary and multifocal HCC. 9
Early data from the SPACE trial using time to
untreatable progression show that confounding factors
(such as tolerability) to systemic treatment when
combined with locoregional treatments may impact on
the results. 11 Neither the assessment of the primary
index lesion nor time to untreatable progression have
been validated sufﬁciently for adoption as a decision aid
in routine practice or as a surrogate for prognosis in
comparative clinical trials.
3. Focal effects of SIRT and targeted therapies
A second limitation of imaging is the effects of
the locoregional treatment on adjacent tissue. Most
locoregional or local ablation techniques cause damage
to the adjacent tissue which may be indistinguishable
from tumour necrosis and mimics tumour growth on
post-interventional scans. Following SIRT for example,
radiation-induced inﬂammatory reactions may provoke
contrast enhancement adjacent to the necrotic or
residual tumour and the border demarcation around the
tumour may vanish. By contrast, with targeted drugs
(anti-angiogenics) the lesion becomes sharply demar-
cated with the loss of perfusion or CM-enhancement.
4. The future
A variety of modalities may be used to assess
local tumour response. However, as outlined previ-
ously, simple size measurements may fail to describe
local tumours response. Thus, functional imaging
such as diffusion-weighted MRI (in mCRC), 12 hepato-
biliary MRI with gadolinium-ethoxybenzyl-diethylene-
triamine pentaacetic acid (Gd-EOB-DTPA-MRI) 13 and
positron emission tomography (PET)/computed tomogra-
phy (CT) 14 in selected tumours are likely to be included
in future guidelines although clinical data with these
techniques are currently still lacking. Validation of new
staging concepts and advanced imaging techniques with
diffusion-weighted MRI in mCRC and Gd-EOB-DTPA-MRI
in HCC are ongoing in clinical trials such as SIRFLOX
and SORAMIC, respectively, which are evaluating the
response to SIRT.
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